Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
2,483.0
10.7 (0.43%)

 

  • STI Straits Times Index
    2,483.0
    10.7 (0.43%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,511.7
    2.5 (0.17%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    23,476.0
    240.6 (1.04%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,217.5
    -1.9 (-0.06%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    23,511.6
    307.0 (1.32%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    4,906.5
    -39.2 (-0.79%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 764.8M
  • Value: 848.5M
  • Rise: 135
  • Fall: 143
  • Unch: 502

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Jiutian Chemical0.053+0.002
Vicplas Intl0.355-0.095
Sembcorp Marine0.143+0.001
OEL0.019+0.001
Singtel2.120-0.020
Synagie0.200-0.010
HPH Trust USD0.136+0.006
Oceanus^0.007-
QT Vascular0.007-
ThaiBev0.595+0.010

World Indices

World Indices
Name Last Change
Nasdaq 10,672.3 +39.3
HSI 23,235.4 -75.7
HSCEI 9,302.6 -68.6
Jakarta 4,945.8 +103.0
Nikkei 225 23,204.6 +116.8
SSE Comp 3,219.4 -3.8
Shanghai A 3,374.1 -4.0
Shanghai B 247.4 +0.8
KOSPI 2,278.8 +6.1

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

Hyphens Pharma HYPHENS PHARMA INTL LIMITED
Quotes 10 Minutes Delayed. Updated at 28 Sep 2020 17:04
Last (SGD): 0.420 Change: -0.010 High: 0.425 Remarks: -
Change (%): -2.33 Low: 0.410
Open 0.425 Yesterday's Close 0.430
Buy Price 0.415 Sell Price 0.420
Buy Volume ('000) 8.0 Sell Volume ('000) 37.1
Cumulative Volume ('000) 824.0 Cumulative Value 342,944
Click to show Stock Prices chart

Key Statistics

EPS (SGD) a 0.02174 Trailing EPS (SGD) e 0.02579 NAV (SGD) b 0.1507
PE a 19.319 Trailing PE f 16.286 Price / NAV b 2.7870
Dividend (SGD) d 0.010000 Cash In Hand (SGD) g 0.0868 Issued & Paid-up Shares c 300,430,000
Dividend Yield (%) d 2.381 Price / Cash In Hand g 4.839 Treasury Shares h -
Beta - 75 Daysi 0.300 R-Squared - 75 Days(%)i 0.31 Market Cap (M) 126.181
Beta - 500 Daysi 0.343 R-Squared - 500 Days (%)i 0.79 Enterprise Value (M) 103.734
Piotroski F Score 6 Exchange Code 1J5 Par Value ( SGD ) n.a.
52 Weeks Volatility (%) 60.1559 6-Month VWAP 0.450 Free Float (%) 20.4
Under CPF Investment Scheme (CPFIS) No
Sector & Industry Wholesale and Retail Trade - Pharmaceuticals: Major
Category Classification Medical & Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 18 Aug 2020.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand.
  9. Beta and R-Squared are calculated in relation to the market index (STI or KLCI) using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference Hyphens Pharma SGX 126.181 19.319 16.286 2.7870 2.381
Industry Medical & Biotechnology SGX 917.197 21.649 20.898 1.3049 2.097
Pharmaceuticals: Major SGX 98.407 2431.015 115.115 4.4092 1.018
Local Peer IX Biopharma SGX 162.946 - - 7.9932 -
Local Peer Pharmesis Intl SGX 6.095 - - 0.5290 -
Global Peer JOHNSON & JOHNSON NYSE 383,496.561 25.365 25.255 6.0894 2.574
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 214,905.597 30.491 29.773 3.9937 2.115
Global Peer MERCK & CO INC NYSE 209,749.873 21.310 20.016 7.5881 2.736
Global Peer PFIZER INC NYSE 200,325.524 12.311 14.137 3.1137 4.033
Global Peer ABBVIE INC NYSE 152,181.291 19.406 22.049 10.3469 4.266
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 145,690.436 108.681 192.241 11.9056 2.468
Global Peer ELI LILLY AND COMPANY NYSE 143,719.182 30.988 25.581 35.1140 1.719
Global Peer BRISTOL-MYERS SQUIBB CO NYSE 134,086.296 38.990 - 2.7312 2.792
Global Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 127,857.439 39.296 10.409 1.7983 2.302
Global Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 125,175.394 21.437 20.408 13.8319 1.647
Other Global Peers GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 (NYSE), TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), WUXI APPTEC (HKEx), HANSOH PHARMA (HKEx), ROYALTY PHARMA PLC (NASDAQ), INNOVENT BIO (HKEx), CUREVAC NV (NASDAQ), REPLIGEN CORP (NASDAQ), CANSINOBIO-B (HKEx), SINOPHARM (HKEx), JUNSHI BIO (HKEx), SH PHARMA (HKEx), HUTCHISON CHINA MEDITECH SPON ADS EACH REPR 5 ORD SHS (NASDAQ), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS (NASDAQ), BAIYUNSHAN PH (HKEx), ALLAKOS INC (NASDAQ), HYGEIA HEALTH (HKEx), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), TURNING POINT THERAPEUTICS INC (NASDAQ), PRINCIPIA BIOPHARMA INC (NASDAQ), HENLIUS-B (HKEx), REATA PHARMACEUTICALS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), CHINARES PHARMA (HKEx), CHINAGRANDPHARM (HKEx), CMS (HKEx), AKESO-B (HKEx), HEPALINK (HKEx), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), ADC THERAPEUTICS SA (NYSE), APELLIS PHARMACEUTICALS INC (NASDAQ), IGM BIOSCIENCES INC (NASDAQ), OPKO HEALTH INC (NASDAQ), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), TRAD CHI MED (HKEx), ZYMEWORKS INC (NYSE), KARUNA THERAPEUTICS INC (NASDAQ), FORMA THERAPEUTICS HLDGS INC (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), UNITED LAB (HKEx), AKCEA THERAPEUTICS INC (NASDAQ), OCUMENSION-B (HKEx), SSY GROUP (HKEx), INNOCARE-B (HKEx), Y-MABS THERAPEUTICS INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), GENERATION BIO CO (NASDAQ), Kimia Farma Tbk. (IDX), AMNEAL PHARMACEUTICALS INC (NYSE), CSTONE PHARMA-B (HKEx), REPARE THERAPEUTICS INC (NASDAQ), ATHENEX INC (NASDAQ), NURIX THERAPEUTICS INC (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), CKLIFE SCIENCES (HKEx), KINIKSA PHARMACEUTICALS LTD (NASDAQ), QUANTERIX CORPORATION (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), Soho Global Health Tbk. (IDX), CONSTELLATION PHARMACEUTICALS INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), PETIQ INC (NASDAQ), TONGRENTANGCM (HKEx), ANNEXON INC (NASDAQ), KEROS THERAPEUTICS INC (NASDAQ), KRYSTAL BIOTECH INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), IMMUNOTECH-B (HKEx), PROVENTION BIO INC (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), HUA MEDICINE-B (HKEx), ORIC PHARMACEUTICALS INC (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), SIGA TECHNOLOGIES INC (NASDAQ), IGBB (Bursa), ODONATE THERAPEUTICS INC (NASDAQ), INOZYME PHARMA INC (NASDAQ), FUSION PHARMACEUTICALS INC (NASDAQ), 89BIO INC (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), APREA THERAPEUTICS INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), SHINEWAY PHARM (HKEx), MIRUM PHARMACEUTICALS INC (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), TRICIDA INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), KALA PHARMACEUTICALS INC (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), FUSEN PHARM (HKEx), BEYONDSPRING INC (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), IMARA INC (NASDAQ), BIOSPECIFICS TECHNOLOGIES CORP (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), DURECT CORP (NASDAQ), AFT PHARMACEUTICALS LTD (ASX), AC IMMUNE SA (NASDAQ), IMMUNIC INC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), PYC THERAPEUTICS LIMITED (ASX), KALEIDO BIOSCIENCES INC (NASDAQ), BSTEAD (Bursa), AMAG PHARMACEUTICS INC (NASDAQ), TOT BIOPHARM-B (HKEx), UROVANT SCIENCES LTD (NASDAQ), PHARMA (Bursa), XERIS PHARMACEUTICALS INC (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), VYNE THERAPEUTICS INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), LANNETT CO INC (NYSE), KALVISTA PHARMACEUTICALS INC (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), POLYPID LTD (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), GAMIDA CELL LTD (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), ESSA PHARMA INC (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), LIQUIDIA TECHNOLOGIES INC (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), DAWNRAYS PHARMA (HKEx), MILESTONE PHARMACEUTICALS INC (NASDAQ), AVENUE THERAPEUTICS INC (NASDAQ), VERU INC (NASDAQ), MUSTANG BIO INC (NASDAQ), PROTARA THERAPEUTICS INC (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), ZHONGZHIPHARM (HKEx), THERATECHNOLOGIES INC (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), CH BIOTECH SER (HKEx), HARROW HEALTH INC (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), BIOMX INC (NYSE American), OBSEVA SA (NASDAQ), RECCE PHARMACEUTICALS LTD (ASX), GENPREX INC (NASDAQ), EVOLUS INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), LANTERN PHARMA INC (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), KOTRA (Bursa), GRITSTONE ONCOLOGY INC (NASDAQ), MEDIWOUND LTD (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), Phapros Tbk. (IDX), Merck Tbk. (IDX), NEW RAY MEDIC (HKEx), IP (SET), NEP INTERLONG (HKEx), EDESA BIOTECH INC (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), EYENOVIA INC (NASDAQ), PAK FAH YEOW (HKEx), CLEARSIDE BIOMEDICAL INC (NASDAQ), TREVI THERAPEUTICS INC (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), ASSERTIO HOLDINGS INC (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), RACE ONCOLOGY LTD (ASX), KITOV PHARMA LTD SPON ADS EACH REP 10 ORD SHS (R/S) (NASDAQ), NOVAN INC (NASDAQ), NOVA (Bursa), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), PALLA PHARMA LTD (ASX), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), ARIDIS PHARMACEUTICAL INC (NASDAQ), CHARMACY PHAR (HKEx), NC HEALTHCARE (HKEx), NOXOPHARM LTD (ASX), BIOHLDG (Bursa), AERPIO PHARMACEUTICALS INC (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), BAUDAX BIO INC (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), MOLECULIN BIOTECH INC (NASDAQ), WAI YUEN TONG (HKEx), ALLENA PHARMACEUTICALS INC (NASDAQ), PAINREFORM LTD (NASDAQ), PROPHASE LABS INC (NASDAQ), IMMURON LIMITED (ASX), TBG DIAGNOSTICS LTD (ASX), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), INVION LTD (ASX), SANAI HEALTH GP (HKEx), EXTRAWELL PHAR (HKEx), ONCTERNAL THERAPEUTICS INC (NASDAQ), MANNATECH INC (NASDAQ), PURAPHARM (HKEx), MEDLAB CLINICAL LIMITED (ASX), JCT (SET), DARE BIOSCIENCE INC (NASDAQ), AGEX THERAPEUTICS INC (NYSE American), ANNOVIS BIO INC (NYSE American), CNS PHARMACEUTICALS INC (NASDAQ), ACER THERAPEUTICS INC (NASDAQ), MILLENDO THERAPEUTICS INC (NASDAQ), SUN BIOPHARMA INC (NASDAQ), HOTH THERAPEUTICS INC (NASDAQ), EXOPHARM LTD (ASX), PHARMAXIS (ASX), ENTERA BIO LTD (NASDAQ), BRICKELL BIOTECH INC (NASDAQ), SPRING BANK PHARMACEUTICALS INC (NASDAQ), SUNZEN (Bursa), ACRUX (ASX), NOVUS THERAPEUTICS INC (NASDAQ), FIJI KAVA LTD (ASX), SINOLIFE UTD (HKEx), PASHUN INT'L (HKEx), ADIAL PHARMACEUTICALS INC (NASDAQ), TITAN PHARMACEUTICAL INC (NASDAQ), CHINA SXT PHARMACEUTICALS INC (NASDAQ), TALI DIGITAL LIMITED (ASX), TIMBER PHARMACEUTICALS INC (NYSE American), CRESO PHARMA LTD (ASX), SUDA PHARMACEUTICALS LTD (ASX), CELLMID LIMITED (ASX), Merck Sharp Dohme Pharma Tbk. (IDX), FARMAFORCE LTD (ASX), TELIGENT INC NEW (NASDAQ)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+0.040
+10.53 %
10 Days -+0.030
+7.69 %
20 Days -+0.005
+1.20 %
Medium Term Return 3 Months -+0.125
+42.37 %
6 Months 0.010+0.231
+127.51 %
1 Year 0.010+0.221
+116.08 %
Long Term Return 2 Years 0.016+0.205
+102.79 %
Annualised Return Annualised --
+42.40 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.180 - 0.625 Change From 1 Year Low +0.240 % Change From 1 Year Low (%) +133.33
Change From 1 Year High -0.205 % Change From 1 Year High (%) -32.80
2 Years Range 0.160 - 0.625 Change From 2 Years Low +0.260 % Change From 2 Years Low (%) +162.50
Change From 2 Years High -0.205 % Change From 2 Years High (%) -32.80
5 Years Range 0.160 - 0.625 Change From 5 Years Low +0.260 % Change From 5 Years Low (%) +162.50
Change From 5 Years High -0.205 % Change From 5 Years High (%) -32.80
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Hyphens Pharma International Limited and its subsidiaries (the "Group") is one of Singapores leading specialty pharmaceutical and consumer healthcare groups leveraging on its diverse footprint in ASEAN countries. The Group has a direct presence in five ASEAN countries, namely, Singapore, Vietnam, Malaysia, Indonesia and the Philippines, supplemented by a marketing and distribution network covering five additional jurisdictions, namely, Hong Kong, Myanmar, Brunei, Cambodia and Oman. Singapore is the Groups regional headquarters, where its strategic planning, finance, regulatory affairs, research and development, legal, business development and logistics operations are based.The Groups core business comprises the following segments: specialty pharma principals, proprietary brands, and medical hypermart and digital. Besides marketing and selling a range of specialty pharmaceutical products in selected ASEAN countries through exclusive distributorship or licensing and supply agreements with brand principals mainly from Europe and the United States, the Group also develops, markets and sells its own proprietary range of dermatological products and health supplement products. In addition, the Group operates a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies, to supply pharmaceutical products and medical supplies.

IPO Performance

Listing Date 18 May 2018 Full Subscription Rate (x) 17.91
No of Placement Shares (M) 23.79 No of Public Offer Shares (M) 3.00 Public Offer Subscription Rate (x) 151.99
IPO Price (SGD) a 0.260 First Day Close (SGD) a 0.275 First Week Close (SGD) a 0.260
Current vs IPO Price (%) +61.54 First Day Gain (%) +5.77 First Week Gain (%) -
Notes:
  1. Adjusted for the following: 23,790,000 Placement Shares do not include the 2,810,000 Reserved Shares.

Reports Download

Report Type Financial Year Ended Download
Annual Report
Annual Report 2019 Dec 2019 Part 1(6.40 MB)
Annual Report 2018 Dec 2018 Part 1(7.14 MB)
IPO Prospectus
IPO Prospectus 2018 May 2018 Part 1(2.57 MB)
Part 2(0.27 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
28 Sep 2020 0.425 0.425 0.410 0.420 824,000 0.4162
25 Sep 2020 0.450 0.455 0.420 0.430 1,319,100 0.4331
24 Sep 2020 0.450 0.465 0.435 0.450 5,929,400 0.4520
23 Sep 2020 0.385 0.470 0.385 0.455 13,958,000 0.4322
22 Sep 2020 0.375 0.385 0.370 0.385 808,300 0.3810
21 Sep 2020 0.395 0.395 0.375 0.380 1,415,000 0.3845
18 Sep 2020 0.405 0.410 0.390 0.390 950,900 0.3988
17 Sep 2020 0.395 0.415 0.395 0.400 1,873,800 0.4047
16 Sep 2020 0.395 0.400 0.390 0.395 396,000 0.3949
15 Sep 2020 0.390 0.415 0.390 0.395 2,264,000 0.4029
14 Sep 2020 0.405 0.410 0.385 0.390 1,113,900 0.3941
11 Sep 2020 0.390 0.405 0.390 0.395 1,223,200 0.3968
10 Sep 2020 0.415 0.415 0.380 0.385 2,334,200 0.3931
09 Sep 2020 0.405 0.415 0.405 0.410 1,368,000 0.4089
08 Sep 2020 0.415 0.425 0.410 0.410 2,722,100 0.4158
07 Sep 2020 0.410 0.425 0.405 0.405 751,100 0.4126
04 Sep 2020 0.400 0.415 0.390 0.410 1,076,700 0.4042
03 Sep 2020 0.415 0.450 0.415 0.420 5,840,600 0.4341
02 Sep 2020 0.425 0.425 0.410 0.410 759,500 0.4168
01 Sep 2020 0.410 0.445 0.410 0.425 4,314,400 0.4322
31 Aug 2020 0.420 0.435 0.410 0.415 1,882,400 0.4179
28 Aug 2020 0.440 0.450 0.415 0.420 2,157,600 0.4289
Summary
Current 2 Weeks
(15 Sep 2020 to 28 Sep 2020)
0.390 0.470 0.370 0.420 29,738,500 -
Previous 2 Weeks
(01 Sep 2020 to 14 Sep 2020)
0.410 0.470 0.370 0.390 21,503,700 -
4 Weeks from
(03 Aug 2020 to 31 Aug 2020)
0.570 0.610 0.370 0.415 118,877,500 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.